Switching effective antiretroviral therapy: A review

Henning Drechsler, William G. Powderly

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

One approach to target the long-term metabolic toxicity and disfiguring body-shape changes associated with antiretroviral therapy is to switch one component of a regimen to an alternative drug, usually from a different class of antiretrovirals. Most commonly, substitutions have involved protease inhibitors, but the thymidine analogue nucleosides, especially stavudine, have been investigated more recently. Certain trends from these studies have emerged. First, if the patient has had sustained viral suppression, switching therapy is generally virologically safe. Second, metabolic disturbances, such as insulin resistance and dyslipidemia, appear to be at least partially reversible. Substitution of other agents for protease inhibitors has not been associated with reversal or improvement in fat redistribution. Studies in which thymidine analogue reverse-transcriptase inhibitors have been switched have reported modest improvements in peripheral lipoatrophy. Larger, controlled, long-term studies and a more standardized approach to definition of metabolic and morphological abnormalities are needed.

Original languageEnglish (US)
Pages (from-to)1219-1230
Number of pages12
JournalClinical Infectious Diseases
Volume35
Issue number10
DOIs
StatePublished - Nov 15 2002

Fingerprint

Protease Inhibitors
Thymidine
Stavudine
Reverse Transcriptase Inhibitors
Dyslipidemias
Nucleosides
Insulin Resistance
Fats
Therapeutics
Pharmaceutical Preparations
Sustained Virologic Response

ASJC Scopus subject areas

  • Immunology

Cite this

Switching effective antiretroviral therapy : A review. / Drechsler, Henning; Powderly, William G.

In: Clinical Infectious Diseases, Vol. 35, No. 10, 15.11.2002, p. 1219-1230.

Research output: Contribution to journalArticle

Drechsler, Henning ; Powderly, William G. / Switching effective antiretroviral therapy : A review. In: Clinical Infectious Diseases. 2002 ; Vol. 35, No. 10. pp. 1219-1230.
@article{ca4e322139e04ab3b3e41c00c392637c,
title = "Switching effective antiretroviral therapy: A review",
abstract = "One approach to target the long-term metabolic toxicity and disfiguring body-shape changes associated with antiretroviral therapy is to switch one component of a regimen to an alternative drug, usually from a different class of antiretrovirals. Most commonly, substitutions have involved protease inhibitors, but the thymidine analogue nucleosides, especially stavudine, have been investigated more recently. Certain trends from these studies have emerged. First, if the patient has had sustained viral suppression, switching therapy is generally virologically safe. Second, metabolic disturbances, such as insulin resistance and dyslipidemia, appear to be at least partially reversible. Substitution of other agents for protease inhibitors has not been associated with reversal or improvement in fat redistribution. Studies in which thymidine analogue reverse-transcriptase inhibitors have been switched have reported modest improvements in peripheral lipoatrophy. Larger, controlled, long-term studies and a more standardized approach to definition of metabolic and morphological abnormalities are needed.",
author = "Henning Drechsler and Powderly, {William G.}",
year = "2002",
month = "11",
day = "15",
doi = "10.1086/343050",
language = "English (US)",
volume = "35",
pages = "1219--1230",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Switching effective antiretroviral therapy

T2 - A review

AU - Drechsler, Henning

AU - Powderly, William G.

PY - 2002/11/15

Y1 - 2002/11/15

N2 - One approach to target the long-term metabolic toxicity and disfiguring body-shape changes associated with antiretroviral therapy is to switch one component of a regimen to an alternative drug, usually from a different class of antiretrovirals. Most commonly, substitutions have involved protease inhibitors, but the thymidine analogue nucleosides, especially stavudine, have been investigated more recently. Certain trends from these studies have emerged. First, if the patient has had sustained viral suppression, switching therapy is generally virologically safe. Second, metabolic disturbances, such as insulin resistance and dyslipidemia, appear to be at least partially reversible. Substitution of other agents for protease inhibitors has not been associated with reversal or improvement in fat redistribution. Studies in which thymidine analogue reverse-transcriptase inhibitors have been switched have reported modest improvements in peripheral lipoatrophy. Larger, controlled, long-term studies and a more standardized approach to definition of metabolic and morphological abnormalities are needed.

AB - One approach to target the long-term metabolic toxicity and disfiguring body-shape changes associated with antiretroviral therapy is to switch one component of a regimen to an alternative drug, usually from a different class of antiretrovirals. Most commonly, substitutions have involved protease inhibitors, but the thymidine analogue nucleosides, especially stavudine, have been investigated more recently. Certain trends from these studies have emerged. First, if the patient has had sustained viral suppression, switching therapy is generally virologically safe. Second, metabolic disturbances, such as insulin resistance and dyslipidemia, appear to be at least partially reversible. Substitution of other agents for protease inhibitors has not been associated with reversal or improvement in fat redistribution. Studies in which thymidine analogue reverse-transcriptase inhibitors have been switched have reported modest improvements in peripheral lipoatrophy. Larger, controlled, long-term studies and a more standardized approach to definition of metabolic and morphological abnormalities are needed.

UR - http://www.scopus.com/inward/record.url?scp=0037111579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037111579&partnerID=8YFLogxK

U2 - 10.1086/343050

DO - 10.1086/343050

M3 - Article

C2 - 12410482

AN - SCOPUS:0037111579

VL - 35

SP - 1219

EP - 1230

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -